We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

Ublituximab (Briumvi, Neuraxpharm) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features'. The ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. This topic was considered by the lead team of the committee, which includes the chair and vice chair.

Review and download supporting evidence. Includes the full guideline if available.

Review and download supporting evidence. Includes the full guideline if available.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

This procedure should only be done as part of a formal research study and a research ethics committee needs to have approved its use. Patient selection should be done by a movement disorders ...

Use the least expensive option of the available treatments (including ublituximab, ocrelizumab and ofatumumab). Take account of administration costs, dosages, price per dose and commercial ...

NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 7 sources, ...

Ublituximab (Briumvi) is available on the NHS. It is a possible treatment for relapsing–remitting multiple sclerosis in adults that is confirmed as active by clinical or imaging features. If you are ...